Immunovant, Inc.

NasdaqGS:IMVT Stock Report

Market Cap: US$2.5b

Immunovant Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:IMVT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
23 Apr 25SellUS$34,742Michael GeffnerIndividual2,349US$14.79
23 Apr 25SellUS$28,471Jay StoutIndividual1,925US$14.79
16 Apr 25SellUS$44,566Eva BarnettIndividual2,993US$14.89
16 Apr 25SellUS$123,900Peter SalzmannIndividual8,321US$14.89
09 Apr 25SellUS$364,941Peter SalzmannIndividual28,094US$12.99
09 Apr 25SellUS$80,135Michael GeffnerIndividual6,169US$12.99
09 Apr 25SellUS$65,002Jay StoutIndividual5,004US$12.99
09 Apr 25SellUS$143,708Eva BarnettIndividual11,063US$12.99
19 Feb 25SellUS$322,058Peter SalzmannIndividual15,439US$20.86
19 Feb 25SellUS$58,700Eva BarnettIndividual2,814US$20.86
19 Feb 25SellUS$42,867William MaciasIndividual2,055US$20.86
22 Jan 25SellUS$62,679Michael GeffnerIndividual2,657US$23.59
22 Jan 25SellUS$51,780Jay StoutIndividual2,195US$23.59
15 Jan 25SellUS$208,900Peter SalzmannIndividual8,767US$24.19
15 Jan 25SellUS$54,757Eva BarnettIndividual2,298US$24.19
15 Jan 25SellUS$56,782William MaciasIndividual2,383US$24.19
13 Jan 25BuyUS$336,900,200Roivant Sciences Ltd.Company16,845,010US$20.00
08 Jan 25SellUS$123,031Peter SalzmannIndividual5,105US$24.10
08 Jan 25SellUS$98,931Eva BarnettIndividual4,105US$24.10
20 Nov 24SellUS$106,228Eva BarnettIndividual4,174US$25.45
20 Nov 24SellUS$85,334William MaciasIndividual3,353US$25.45
20 Nov 24SellUS$424,811Peter SalzmannIndividual16,692US$25.45
20 Nov 24SellUS$92,893Mark LevineIndividual3,650US$25.45
23 Oct 24SellUS$80,912Jay StoutIndividual2,740US$29.53
23 Oct 24SellUS$94,171Michael GeffnerIndividual3,189US$29.53
23 Oct 24SellUS$128,780Mark LevineIndividual4,361US$29.53
16 Oct 24SellUS$94,172Eva BarnettIndividual3,271US$28.79
16 Oct 24SellUS$91,783William MaciasIndividual3,188US$28.79
16 Oct 24SellUS$82,339Mark LevineIndividual2,860US$28.79
16 Oct 24SellUS$261,845Peter SalzmannIndividual9,095US$28.79
09 Oct 24SellUS$131,838Peter SalzmannIndividual4,460US$29.56
09 Oct 24SellUS$152,589Eva BarnettIndividual5,162US$29.56
21 Aug 24SellUS$480,052Peter SalzmannIndividual15,068US$32.32
21 Aug 24SellUS$120,045Eva BarnettIndividual3,768US$32.32
21 Aug 24SellUS$96,437Julia ButchkoIndividual3,027US$32.32
21 Aug 24SellUS$96,437William MaciasIndividual3,027US$32.32
21 Aug 24SellUS$104,976Mark LevineIndividual3,295US$32.32
24 Jul 24SellUS$111,456Mark LevineIndividual4,015US$27.76
24 Jul 24SellUS$95,939Michael GeffnerIndividual3,456US$27.76
24 Jul 24SellUS$78,089Jay StoutIndividual2,813US$27.76
17 Jul 24SellUS$257,888Peter SalzmannIndividual8,685US$30.55
17 Jul 24SellUS$85,132Julia ButchkoIndividual2,867US$30.55
17 Jul 24SellUS$92,733Eva BarnettIndividual3,123US$30.55
17 Jul 24SellUS$90,386William MaciasIndividual3,044US$30.55
17 Jul 24SellUS$74,382Mark LevineIndividual2,505US$30.55
09 Jul 24SellUS$129,609Peter SalzmannIndividual4,619US$28.06
09 Jul 24SellUS$42,848Julia ButchkoIndividual1,527US$28.06
09 Jul 24SellUS$133,201Eva BarnettIndividual4,747US$28.06
22 May 24SellUS$96,125Mark LevineIndividual3,242US$29.65
22 May 24SellUS$96,274William MaciasIndividual3,247US$29.65
22 May 24SellUS$96,274Julia ButchkoIndividual3,247US$29.65
22 May 24SellUS$479,233Peter SalzmannIndividual16,163US$29.65
22 May 24SellUS$119,845Eva BarnettIndividual4,042US$29.65

Insider Trading Volume

Insider Buying: IMVT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of IMVT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,514,8560.784%
VC/PE Firms9,500,0004.91%
Institutions85,676,55144.3%
Public Companies96,650,34150%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.9%.

Top Shareholders

Top 25 shareholders own 103.82% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
56.9%
Roivant Sciences Ltd.
96,650,341US$1.4b0%no data
10.2%
FMR LLC
17,237,139US$253.4m31.6%0.01%
5.59%
Deep Track Capital, LP
9,500,000US$139.7m58.3%4.91%
4.08%
The Vanguard Group, Inc.
6,936,859US$102.0m3.85%no data
3.91%
T. Rowe Price Group, Inc.
6,639,368US$97.6m10%0.01%
3.21%
Baker Bros. Advisors LP
5,457,881US$80.2m220%0.65%
3.16%
BlackRock, Inc.
5,364,222US$78.9m4.3%no data
2.65%
Armistice Capital LLC
4,500,000US$66.2m16.3%1.66%
1.82%
State Street Global Advisors, Inc.
3,087,095US$45.4m14.4%no data
1.67%
Perceptive Advisors LLC
2,844,072US$41.8m33%1.57%
1.55%
Alpine Global Management, LLC
2,626,692US$38.6m21.7%13.36%
0.98%
Geode Capital Management, LLC
1,672,590US$24.6m10.4%no data
0.97%
Two Seas Capital LP
1,642,772US$24.1m8.68%3.22%
0.88%
Woodline Partners LP
1,497,869US$22.0m133%0.14%
0.7%
Pictet Asset Management Limited
1,188,578US$17.5m1.1%0.01%
0.69%
Hood River Capital Management LLC
1,175,863US$17.3m2.64%0.26%
0.66%
Viking Global Investors LP
1,114,827US$16.4m-20.8%0.05%
0.6%
UBS Asset Management AG
1,011,105US$14.9m16.2%no data
0.58%
Morgan Stanley, Investment Banking and Brokerage Investments
981,813US$14.4m61.1%no data
0.57%
Rock Springs Capital Management LP
975,803US$14.3m7.34%0.81%
0.57%
ADAR1 Capital Management, LLC
968,866US$14.2m23%2.64%
0.5%
StemPoint Capital LP
853,472US$12.5m-23.7%4.16%
0.5%
Goldman Sachs Group, Investment Banking and Securities Investments
843,225US$12.4m62.8%0.01%
0.48%
Aberdeen Group Plc
819,477US$12.0m54%0.01%
0.45%
Principal Global Investors, LLC
760,608US$11.2m-3.95%0.01%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 03:27
End of Day Share Price 2025/05/20 00:00
Earnings2024/12/31
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Immunovant, Inc. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jason Matthew GerberryBofA Global Research
Louise ChenCantor Fitzgerald & Co.